CRO Oncology Launch Bottle, Arati Rao, MD, named First Counselor | News

SAN FRANCISCO, June 1, 2022 / PRNewswire / – Bottle announced that they will expand their CRO to oncology. This interesting post appears after their successful launch in dermatology and Ophthalmology earlier this year.

Arati Rao, MD, head of the clinical development department at PACT Pharma, will advise the Vial team on the design and development of the oncology CRO. Dr. Rao and the Vial team will work closely together to create a CRO optimized for the greatest needs of sponsors.

The new Oncology CRO program will focus on speeding up performance and better test results for Oncology sponsors. By deploying Vial’s test-supported test management system, which integrates eSource, ePRO, EDC and CTMS into an operating system, CRO will enable testing to be conducted with maximum efficiency.

Dr. Rao has been a principal investigator (PI) in several studies on hematologic malignancies and was a clinical researcher funded by the NIH (National Institutes of Health). She specializes in caring for elderly patients with hematological malignancies, particularly acute myeloid leukemia. Prior to joining PACT Pharma, Dr. Rao was the Executive Director of Kite Pharma and the Medical Director (Clinical Oncology Research) at Gilead Sciences. Dr. Rao is a former associate professor of medicine Duke University Faculty of Medicine, where she completed both scholarships in hematology-oncology and geriatrics, in addition to residency after medical school.

Joining Viola, Dr. Rao said, “When I left Duke to join the biotechnology industry, I wanted to move the needle to cancer patients and influence the development of therapeutic agents on a larger scale. The decision to join Vial as an advisor is driven by the same motivation. I believe that Viol can change the field of cancer research for the better, and I am very happy to help them in this way. “

About Vial: Vial’s mission is to conduct clinical trials with faster performance and higher quality to bring new treatments to market. Vial has more than 100 employees and is located in San Francisco, California. Vial is collaborating with dermatologists, ophthalmologists and oncologists to support their research teams, and has established a network of more than 35 clinics that have contributed to more than 750 trials. The network of clinics conducts tests from phase I to phase IV.

See the full issue here.

See original content for multimedia downloads:


Source link